Podcasts about trd

Summary: *Ron Jones discusses treatment resistant depression (TRD), which occurs when multiple classes of antidepressant medications fail to provide relief. *TRD is described as a subcategory of major depressive disorder, unrelated to therapy but linked to the ineffectiveness of psychotropic medications. *Ron shares his personal experience with TRD, highlighting the frustration and discouragement of ineffective treatments and the lengthy process of testing medications. *He suggests that emotional and mental needs, when unmet, can lead to chemical imbalances, and treating only the symptoms without addressing underlying issues is insufficient. *Jones emphasizes the importance of understanding one's identity in relation to God, suggesting that misalignment can contribute to mental health issues. *He recounts a pivotal moment in a church service where he felt the Holy Spirit's guidance, leading to a significant change in his depression. *Jones discusses the role of community, vulnerability, and addressing lies or misconceptions about oneself as crucial steps in the healing process. *He advocates for the recognition of negative emotions as truthful indicators and encourages seeking the Holy Spirit's guidance for healing. *Jones stresses the importance of relational accountability and having supportive people in one's life to provide honest feedback. *He concludes by affirming the possibility of finding hope and new life even after experiencing deep depression, through a relationship with Christ and understanding one's true identity. PODCAST INTRO: My guest today, Ron Jones, is a pastoral counselor and mental health advocate and he stopped by to share his first-hand experiences and insights into his victory over treatment-resistant depression (TRD). This discussion touches on the complexities of living with TRD, the challenges of traditional treatment methods, and the importance of having a strong identity in Christ and growing in faith throughout the healing process. What is Treatment-Resistant Depression? Treatment-resistant depression is a severe form of major depressive disorder. Ron explained that clinically, it is defined as depression that does not respond to at least three different classes of antidepressant medications. Ron also shared that this condition is not merely about resistance to therapy but is specifically linked to the ineffectiveness of psychotropic medicines. The Struggle with Traditional Treatments Ron describes the frustration of navigating the medical system, which often prioritizes treating symptoms over addressing root causes. He likens the process to taking aspirin for a headache without investigating the underlying cause. He even pointed out that this approach can be disheartening, especially when medications take weeks to show results, if at all. A Journey of Identity and Faith Throughout his journey, Ron emphasizes the importance of understanding one's true identity. He believes that much of mental illness stems from a misalignment between who we are and who we perceive ourselves to be. For Ron, this journey of self-discovery was deeply intertwined with his faith, which provided a foundation and a source of hope. This foundation withstood 13 years of struggling AND also provided room for growth and intimacy with Christ as he searched how to get out from under his depression. As shared in then opening clip….Ron was desperately clinging to hope God and yet had no hope. Steps Toward Healing Ron offered practical steps for those struggling with depression: Evaluate Your "Have To's": Examine the non-negotiables in your life that might be contributing to your stress and consider whether they are truly necessary. Identify Primary Lies: Reflect on the negative emotions you feel most often and ask the Holy Spirit to reveal the first time you felt this way. Listen for the Holy Spirit: Spend time in silence, asking the Holy Spirit, "What's We most important thing I could hear right now?" and be open to whatever answer comes without editing it. Something I added, only because I have to do this: when I'm seeking God for an answer I have learned that I need to write it down. It is very commen for me to forget the details of what He spoke into my spirit. If you want to add a #4: Write down what you hear the Holy Spirit speak into your spirit and refer to it as often as you need to. Conclusion Ron's story gives us a deeper revelation about Treatment Resistant Depression because it's from his personal experience; his 13 year battle to find relief. His faith, community, and self-reflection was instrumental in overcoming his TRD. While traditional treatments may fall short mainly because they're go to is to fix things with medicine vs looking at a more holistic approach that would include a deep dive into one's identity. So Ron's journey offers hope and encouragement to those facing similar struggles, reminding us that there is always a path to discovering the benefits of knowing the truth and having a stronger identity. Live Loved and Thrive! @alifeofthrive.com Sherrie Pilk With regard to the acronyms you'll hear Ron use, here is what they stand for (this info is more current than the audio intro to this podcast episode): SSRIs - (Selective Serotonin Reuptake Inhibitors) are a class of antidepressants that help treat depression Sozo is a practice/method used by some Christian ministries to describe their approach to inner healing, which focuses on restoring broken relationships with God and healing past trauma (for more info check out sozo.org)  SNRIs - Serotonin-Norepinephrine Reuptake Inhibitors PCP - Primary Care Physician BPD - Borderline Personality Disorder Resources along the same topic: Unrelenting Pain Known as The Suicide Disease (CRPS), with Darci Steiner -  https://alifeofthrive.com/wp-admin/post.php?post=9563&action=edit Autoimmune Disease, Pulmonary Fibrosis and Faith, with Sara Salazar - https://alifeofthrive.com/2021/09/01/autoimmune-disease/ Hope in the Midst of Chronic Illness, with Sara Willoughby - https://alifeofthrive.com/2025/01/01/hope-in-the-midst-of-chronic-illness-with-sara-willoughby/ Connect with Ron: Ron's podcast w/his friend (Nick): https://podcasts.apple.com/us/podcast/ron-and-nicks-best-friend-podcast/id1599899345 Amazon link to Ron's most recent book - The Little Book of Forgiveness - The Pathway to Freedom: https://www.amazon.com/Little-Book-Forgiveness-pathway-freedom/dp/B0DYNXWKBW/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.oljVyfzmkcvd-tRRqhc8qzcDCCeB-vKQpdasKmcPpGyLFkFehAMYradfiTGZARL3MVN6ar_YRewiXpEMrwt-ig.0u01g9j57uS-UD4NfXgrNw4IxQKkAQYxAoW0rJG8AV0&qid=1743803194&sr=8-1 Ron's Bio: R. Kenward Jones is a disruptive teacher, writer, podcaster (who isn't these days?), counselor, husband, father and grandfather.  He holds a bachelor's degree in mechanical engineering and master's degrees in biblical studies and counseling.  His debut novel, Buried at Sea, was published by Penmore Press in 2022.  Daily, he writes proverbs, parables and prayers and shares them on his Facebook page and website to inspire and encourage. R. Kenward Jones is a US Navy veteran and served as both an enlisted man and officer for 12 years before he left the military to become a pastor.  After a 13-year long bout with treatment resistant depression he left the ministry to reset his life.  He knows the Valley of the Shadow of Death and the power of personal Creativity as the way through it and out of it. Currently he works as a counselor and teaches the 515A “zero excuses” bootcamp at the local YMCA.  He and Tina, his high school sweetheart, have been married for 40 years, have two children and one grandchild, and live in Southeastern Virginia although they still consider the Shenandoah Valley to be their “home.”  R. Kenward Jones enjoys life and joy tempered by suffering and more than anything wants to help other sufferers experience the same.

➡️ Like The Podcast? Leave A Rating: https://ratethispodcast.com/successstory In this "Lessons" episode, Adrian Brambila, Financial Freedom Expert, reveals how adopting a “rich” mindset—rooted in abundance, ownership, and internal control—turned his side hustle into a seven-figure empire. He breaks down the difference between broke, poor, and rich mindsets, shows how shedding inherited scarcity scripts frees you to invest, spend, and grow wisely, and introduces the TRD framework (Time, Return, Dollars) as the cornerstone of lasting wealth. Learn why shifting to an internal locus of control empowers you to consistently execute proven money tactics and transform entrepreneurial risk into legacy-building success.➡️ Show Linkshttps://successstorypodcast.com YouTube: https://youtu.be/_x3FzKPsQ_U Apple: https://podcasts.apple.com/us/podcast/adrian-brambila-serial-entrepreneur-author-why-you/id1484783544 Spotify: https://open.spotify.com/episode/6rJYGaEztg4qJ8ipk8dbqF ➡️ Watch the Podcast on YouTubehttps://www.youtube.com/c/scottdclary See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week we road test two vehicles with strong all-terrain credentials: the 2025 Toyota Tacoma TRD Pro Hybrid and the 2025 Lexus LX 700h. Co-host Chris Teague put the Toyota through its paces as winter finally turns to spring in Maine. Host Jack Nerad, accompanied by most of his immediate family, tested the luxury Lexus during a extended weekend in Texas. Both vehicles pair a hybrid powertrain with off-road-focused equipment, so there are interesting parallels between the two in addition to their obvious — and not-so-obvious differences. The Tacoma uses the i-FORCE MAX system, combining a turbocharged 2.4-liter engine and electric motor for a total output of 326 horsepower and 465 lb-ft of torque. The TRD Pro's standard equipment includes part-time four-wheel drive, FOX QS3 adjustable shocks with rear remote reservoirs, and 33-inch Goodyear tires on 18-inch black alloy wheels. Unique to the TRD Pro, IsoDynamic Performance Seats use an air-over-oil shock system designed to reduce body movement on rough terrain. Exterior elements include a TRD grille, cat-back exhaust, and the exclusive Mudbath paint option. Inside, the Teagues got the benefit of the TRD Pro's 14-inch touchscreen with Toyota's latest multimedia system, a 12.3-inch digital instrument cluster, wireless Apple CarPlay and Android Auto, and JBL audio. The truck had Toyota Safety Sense 3.0, offering adaptive cruise control, lane tracing assist, road sign recognition, and proactive driving assist with support features like trailer backup guidance and a digital rearview mirror. While the Teagues certainly didn't suffer, the Nerad family basked in the ultra-luxury of the 2025 Lexus LX 700h Overtrail. The full-size premium SUV combines hybrid performance, off-road functionality, and upscale features that set it apart from previous LX editions. Powered by a twin-turbocharged 3.4-liter V6 with a hybrid system that produces 457 horsepower and 583 lb-ft of torque, it uses a 10-speed automatic transmission and offers full-time 4WD. While it offered a boulevard ride as we discovered on our way to and from Globe Life Field, the 700h Overtrail is loaded for bear on the off-road front. It includes Crawl Control, Active Height Control, and Multi-Terrain Select, plus 33-inch all-terrain tires, locking differentials, and a reinforced platform to support and waterproof the hybrid battery. Inside, the cabin offers massaging, ventilated front seats, heated rear seats, a wireless phone charger, and a cool box. As we did some house-hunting, we made extensive use of the 12.3-inch touchscreen with Lexus Interface, wireless Apple CarPlay and Android Auto, cloud-based navigation, and head-up display. Of course, we'll offer even more detail in this episode. Our guest this week is Frank Hanley, Senior Director, Automotive Benchmarking at J.D. Power. In his interview with Host Jack Nerad, he'll be discussing a very important issue going forward — AI in cars, so look for that. We're certain you'll appreciate Frank's insight. In the news this week we'll discuss a J.D. Power analysis of what the proposed tariffs would do to vehicle prices. The conclusions might surprise you, and we'll have all the details. The state of New York is battling the federal government over its congestion tolls, and it has implications for anyone who's planning to travel into a big city. Plus, Chrysler is celebrating its one-hundredth birthday, and we'll have a look back at some of that company's innovations through the years. It's an impressive list. So we have a lot to talk about this week. It's a jam-packed show. New America on the Road Radio Affiliate We'd like to welcome AM-1550, SLC Sports Radio in Salt Lake City and throughout the Salt Lake valley, to America on the Road. Our special thanks to Program Director Dino Costa, who also hosts a great weekday show on AM-1550. Jack Nerad's newest book Jack is now offering his newest crime novel, Only One Thing Stays the Same,

　2025年の全日本スーパーフォーミュラ選手権は第1大会の鈴鹿、第2大会のもてぎを終えているが、今シーズンTRD01Fエンジンを使う車両に貼られる共通のロゴに変化があることにお気づきだろうか。エンジン名には『TRD』の名 […]

➡️ Like The Podcast? Leave A Rating: https://ratethispodcast.com/successstory In this “Lessons” episode, Jaspreet Singh, financial educator, uncovers the hidden systems that keep wage earners poor while investors prosper—revealing how the TRD framework (Time, Return, Dollars) drives lasting wealth, why automating a 75/15/10 split for spending, investing, and saving jump-starts your financial growth, and how inflation quietly transfers value from non-investors to those who hold appreciating assets—empowering you to take control of your money, overcome systemic disadvantages, and build genuine, long-term wealth.➡️ Show Linkshttps://successstorypodcast.com YouTube: https://youtu.be/Ia6fJmPwDwA Apple: https://podcasts.apple.com/us/podcast/jaspreet-singh-founder-of-minority-mindset-the-lies/id1484783544 Spotify: https://open.spotify.com/episode/20jMurtYLQHYsO21lKWGqT ➡️ Watch the Podcast on YouTubehttps://www.youtube.com/c/scottdclary See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

En España los coches japoneses anteriores a los años 90 son casi desconocidos… y hay coches realmente espectaculares, interesantes y muy curiosos. Os he traído 10 y como siempre, mi reto, es descubriros alguno desconocidos para vosotros… ¿lo conseguiré? En España, salvo Canarias, no comenzaron a importarse los coches japoneses hasta la década de los 80 y no llegan a ser realmente populares hasta los años 90. Al otro lado del “charco” sois mucho más afortunados y a veces no entendéis porque hay coches, como algunos de estos, prácticamente desconocidos en España. Además, el mercado japonés es muy particular y también os he traído versiones exclusivas o “casi” para el mercado interior. Toyota Century (1967). Vamos a hablar en un coche de lujo, super lujo, poco conocido que Toyota fabricó de forma casi artesanal y con cuenta gotas desde 1967 hasta 2023 como limusina y desde entonces hasta nuestros días, como SUV de lujo. Toyota Sprinter Trueno AE86 (1983). Es un coche muy popular en algunos ambientes, gracias a las películas de la serie “Initial D”, al manga y al Drift. No soy fan de ninguna de estas cosas, pero sí del Trueno, de menos de una tonelada de peso y sobre todo con el motor TRD de “Toyota Race Development”, de 1,6 litros, 4 cilindros, 20 válvulas, turbo y 220 CV a… ¡cerca de 10.000 rpm! Fue una versión especial de TRD muy minoritaria. Mitsubishi Debonair AMG (1987). Si te hablan de AMG enseguida vas a pensar en Mercedes-Benz y, de hecho, desde 1999, es propiedad de la marca alemana. En los años 80, AMG preparaba coches a cualquier marca que se lo pidiese y le pagase… como fue el caso de Mitsubishi. En esta lista encontrarás dos Mitsubishi AMG. Nissan Silvia (1988). El primero, aparecido en 1965 me parece realmente bonito, me recuerda a los Iso Rivolta… una marca que, desde luego, merece un video. Pero he elegido el S13 de 1988, que ganó en su país el premio al mejor coche japones y que, hasta donde yo sé, no se exportó fuera de Japón, como sí sucedió con algunos de sus sucesores, con la denominación Nissan 200 SX o similares. La versión más alta de gama fue un 2 litros turbo de unos 200 CV y hubo una rara variante descapotable fabricada por Autech Japan que hoy en día son verdaderas rarezas muy cotizadas. Subaru Rex Supercharged VX (1988). Os he traído este Subaru, porque quería incluir algún coche de esta marca. Un coche de apenas 3,19 metros de largo por 1,39 metros de ancho, con un motorcito por supuesto bóxer bicilíndrico de 550 cm3 y que gracias al turbo consigue 55 CV para menos de 700 kg… Mitsubishi Galant AMG (1989). A pesar del relativo éxito del Debonair AMG se ve que Mitsubishi quedó contenta con esta relación y quizás el mejor exponente de estos casi desconocidos Mitsubishi AMG fue este Galant. La base de partida era mejor y gracias a AMG los motores atmosféricos de 2 litros y 4 cilindros llegaron a ofrecer más 170 CV a más de 8.000 rpm. Mitsubishi FTO (1994). Este FTO, derivado de la plataforma del Galant, no era tan ambicioso. Pero era bonito, con un chasis muy afinado, tracción delantera y que con su motor V6 de 2 litros, primero con 180 CV y luego con distribución variable y 200 CV, era muy divertido y agradable de llevar… una joya, sin duda. Honda Integra Type R DC2 (1995). Una verdadera joya, muy apreciado por los aficionados al drift, refinado y con tracción delantera. Lo mejor de este modelo era su motor, una variante de B18C de 1.8 litros, por supuesto con distribución VYEC, que en su versión para el mercado japones ofrecía 200 CV y subía… ¡hasta casi 9.000 rpm! Toyota Mega Cruiser (1995). Te puede parecer un Hummer, pero no lo es… o sí, el Hummer “a la japonesa”. Su motor era curioso, un enorme 4,1 litros de solo 4 cilindros y unos escasos 153 CV, que parecen pocos para mover las más de 2 toneladas y media que pesaba ese coche. Otra curiosidad: A baja velocidad cuenta con dirección a las cuatro ruedas, para mejorar su maniobrabilidad. Nissan Pulsar VZ-R N1 (1998). Y cerramos con el coche más moderno que nació en la que todavía era una era dorada para estos deportivos que podemos clasificar con “Super GTi” y que nacieron a la sombra de una categoría definida para la competición y que de denominaba N-1 que limitaba los motores a 1.6 litros atmosféricos. Conclusión. ¿Recordáis cuando al comenzar el canal algunos me acusaban de que no me gustaban los coches japoneses? Incluso hicimos un vídeo, casi en plan de “coña” titulado “¡No me gustan los coches japoneses!” en el que se decía casi lo contrario… ¡Como no me van a gustar los coches japoneses! Y menos coches como estos 10 que os he traído. ¿He conseguido el reto? ¿Había alguno o algunos que no conocieseis?

Just as 7-Eleven offers too much good stuff, that's what we have in this week's episode of America on the Road. We've been driving a lot of interesting vehicles lately, and so today we thought we'd bring you not two road tests but four — 2025 Toyota Tundra, 2025 Lincoln Nautilus, 2025 Mazda CX-50, 2025 Hyundai Elantra N Line. It's a fascinating quartet of vehicles each with something special to bring to the table. Our Toyota Tundra test vehicle was a 4x4 SRS CrewMax 5.5 that blends rugged capability with modern features, offering a spacious cabin for five and a 5.5-foot composite bed equipped with a power outlet, LED lighting, and an integrated deck rail system. Powered by a 389-horsepower 3.4-liter twin-turbo V6 paired with a 10-speed automatic transmission, it features part-time four-wheel drive and off-road-ready suspension. This model is equipped with the optional TRD Rally Package, adding 18-inch TRD alloy wheels, Bilstein shocks, skid plates, Crawl Control, Multi-Terrain Select, and unique TRD interior and exterior styling. Additional accessories like a TRD performance air filter, bed mat, and wheel locks further boost its practicality and rugged appeal. The big question is whether the turbo V6 matches the ability of a V8. And is the pricey TRD Rally Package worth the added price? And how does the new hybrid version of the Mazda CX-50 stack up? It pairs a 2.5-liter four-cylinder engine with three electric motors, an EV battery, and an electronically controlled CVT to deliver 219 horsepower and 163 lb-ft of torque, along with standard electric all-wheel drive. It features Mazda's Mi-Drive modes for power and trail driving, hill launch assist, and a 1,500-pound towing capacity. The exterior is sharp with LED headlights, a panoramic moonroof, roof rails, and a power rear liftgate. Inside, the CX-50 Hybrid seats five and offers leather-trimmed seats, heated front seats, a heated leather-wrapped steering wheel, a power driver's seat with memory, and a wireless phone charger. Wireless Apple CarPlay and Android Auto, rain-sensing wipers, a wiper de-icer, keyless entry, and an electric parking brake round out the vehicle's feature list. Host Jack Nerad took this one to the desert and back, and we'll have his full report. Meanwhile, co-host Chris Teague took the wheel of the 2025 Lincoln Nautilus and the 2025 Hyundai Elantra N Line. He found the Nautilus offers a refined interior with a standard 48-inch panoramic display, wireless Apple CarPlay and Android Auto, and Lincoln's new Digital Scent system for a personalized cabin experience. Two powertrain choices are available: a 250-horsepower turbocharged four-cylinder and a 310-horsepower hybrid, both paired with standard all-wheel drive. Additional features include available BlueCruise 1.2 hands-free driving technology, premium leather seating, and an optional Revel Ultima 3D audio system. The 2025 Elantra N Line features a sport-tuned chassis, a 201-horsepower turbocharged 1.6-liter engine, and a seven-speed dual-clutch automatic transmission for sharper performance than its siblings. It comes with 18-inch alloy wheels, unique N Line exterior styling, a black mesh grille, and a sports interior with leather-trimmed seats and alloy pedals. Technology highlights include a 10.25-inch touchscreen with navigation, wireless charging, and Hyundai's Bluelink+ connected services. So how does it match up with its most direct competitor, the Honda Civic Si? Chris and Jack will have the answers for you. In the news this week, we have a crisis on our hands, and it's not tariffs; it's uninsured motorists. They are costing each of us who has car insurance billions of dollars each year. We'll tell you what we learned about it a little later in the show. Of course, there is a lot of buzz right now about tariffs in the auto industry. We'll tell you what is real and what is hype and give you thoughts on how you should proceed if you're planning to buy a car this year.

So in this podcast, we talk with Chris from E3 Spark Plugs. Chris is a huge Toyota fan, so we discuss the current 'energy' in the Toyota lineup (GR & TRD models), plus their courage to speak-out against all the recent misinformation surrounding the EV push. We also discuss Chris's role in E3 Spark Plugs.... and spark plug 'myths & truths' in general.

David Wilson, President of Toyota Racing Development USA (TRD), reflects on his remarkable career, Toyota's groundbreaking journey in NASCAR, and the future of motorsports in this heartfelt keynote at EPARTRADE's 5th Annual Race Industry Week.

This- is-CNN. No, that THAT CNN...This is Chapa News Network! WE have late-breaking news developments on 2 fronts: 1. The ACOG has released a clinical update (ACOG ROUNDS) in response to a recent study associating the RSV vaccine and GBS (we covered this study in a past episode). 2. The FDA has EXPANDED the label for an intranasal therapy for Treatment Resistant depression (TRD). Listen in for details.

Credits: 0.50 AMA PRA Category 1 Credit™, 0.50 ABIM MOC or 0.41 AANP, including 0.41 AANP Pharm   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/Podcast/when-ssris-are-not-enough  Overview: In this podcast, expert faculty will discuss how the heterogeneity of major depressive disorder (MDD) symptoms, the frequency of residual symptoms, and the common occurrence of treatment-resistant depression (TRD) indicate a pathophysiology that is complex and multifactorial. The faculty will provide an overview of the current understanding of MDD pathophysiology and discuss how current standard-of-care treatments often fail to comprehensively target these mechanisms, emphasizing how future treatment developments can focus on under-addressed pathophysiological mechanisms, paving the way for personalized MDD treatments that target individual symptom profiles. 

Ranches have long been at the beating heart of Texas — first, as working plots; then, as legacy land. During the pandemic, the properties acquired a new sheen, attracting city-weary Texans and would-be cowboys willing to spend tens of millions of dollars for some peace and quiet and peace of mind. Four years later, demand has come roaring back. TRD's Joe Lovinger talks with one of the state's prolific ranch brokers to find out what's drawing all of that dollar volume to the desert.

The SKATCAST Network presents:The SKATCAST Show #146 with the Script KeeperToday's Skit-SKATs:[ Talking Pets | 1:00 ] - "Doorbell Day 2" - With Halloween approaching, the dogs of the neighborhood discuss their situation and discover a hidden truth. It's about butts.[ Super Epic Space Stories | 12:45 ] - "Clone-o-Ween 2" - You can find "Clone-o-Ween 1" in Patreon (Inside Scooper 105). This episode follows the three clones D-1-X, B-45-TRD and A-55 as they experience their first Halloween. It just happens to be on an alien spaceport that doesn't celebrate and kind of hate humans. Extra space-dumb![ Santa Claus: Crime Fighter | 24:49 ] - "Santa-Ween" - Santa and Batman tackle a few baddies on the naughty list and Satan tales a stroll topside on his favorite night of the year.We hope you have an extra excellent Tuesday!Visit us for more episodes of SKATCAST and other shows like SKATCAST presents The Dave & Angus Show plus BONUS material at https://www.skatcast.com Watch select shows and shorts on YouTube: bit.ly/34kxCneJoin the conversation on Discord! https://discord.gg/mVFf2brAaFFor all show related questions: info@skatcast.comPlease rate and subscribe on iTunes and elsewhere and follow SKATCAST on social media!! Instagram: @theescriptkeeper Facebook: https://www.facebook.com/scriptkeepersATWanna become a Patron? Click here: https://www.patreon.com/SkatcastSign up through Patreon and you'll get Exclusive Content, Behind The Scenes video, special downloads and more! Prefer to make a donation instead? You can do that through our PayPal: https://paypal.me/skatcastpodcast Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

In the latest episode of Deconstruct, TRD's Suzannah Cavanaugh finds out how loan specialists fix bad debt – or at least try to – by talking with loan workout specialists Rob Verrone and Job Warshaw of Iron Hound. Verrone works with sponsors to hash out modifications for distressed CMBS debt, and Warshaw brings perspective from the other side of the table — he spent three decades heading up negotiations for special servicer LNR Partners.

In less than one cycle, New Jersey-based investor Shaya Prager went from total unknown to the owner of millions of square feet in suburban office properties across the country. Now, as the market turns, he's mixed up with allegations of fraud and at risk of losing much of his fast-grown portfolio. On the latest episode of Deconstruct, TRD's Suzannah Cavanaugh and Joe Lovinger talk with fellow reporters Jess Hardin and Sam Lounsberry to break down the curious case of Shaya Prager.

SummaryIn this conversation, the hosts discuss their recent experiences and catch up with each other. Kevin shares his experience helping a friend clean out his house and garage, which included throwing away a large amount of junk. They also talk about motorcycles and the current state of the motorcycle industry. They discuss the popularity of cafe racer-style bikes and the lack of technological advancements in motorcycles compared to cars. The conversation touches on the decline in motorcycle ownership and the changing demographics of motorcycle riders. In this part of the conversation, the hosts discuss their go-to NATO straps for their watches. They mention different brands like Cheap NATO Straps, Crown and Buckle, and Blue Shark. They also talk about the comfort and versatility of NATO straps. The conversation then shifts to the topic of electric cars, specifically the Tesla Semi catching fire and the potential safety concerns of electric vehicles. They also mention the rumor of Toyota working on a new MR2 and the discontinuation of the Toyota Supra. The hosts express their excitement for the new MR2 and discuss the design and performance of the car. They also touch on the Lexus LC 500 and its lack of popularity despite its attractive design. The conversation ends with a suggestion for Toyota to create a dedicated sports car segment under the TRD brand. In this conversation, the hosts discuss various car models and modifications. They talk about the Toyota GR 86 and its price point compared to other sports cars. They also mention the Acura Integra race version and the BMW M5 wagon. The hosts share their thoughts on front-wheel drive vehicles and the weight of cars. They discuss their own car modifications and future plans. The conversation ends with a whiskey recommendation.

Denny Hamlin is back after a rough couple of days on and off the track. On Thursday, the No. 11 team was given an L2 penalty for an engine-rule violation. Denny explains what happened at TRD that caused NASCAR to punish him. He also talks about the impact this will have during the Playoffs. On Saturday, things got worse when he was involved in a massive wreck that ended his race. Denny watched the rest of the race from his bus, where he saw Harrison Burton get the win and punch his Playoff ticket. Denny and Jared also discuss if Christopher Bell should have jumped to the outside lane and moved in front of Burton before Burton made his last push. After a crazy wreck last week, NASCAR made a slight change to the cars to try and prevent them from going airborne. On Saturday, we saw Michael McDowell come off the ground without flipping over. But then, Josh Berry flipped onto his roof before hitting the wall.  While both wrecks looked bad, Denny still isn't worried about cars coming off the ground. The guys also talk about the massive implications that come from Burton winning on Saturday. For Wood Brothers Racing, it was a big financial win. On the flipside, drivers on the bubble lost one more available playoff spot with only one race in the regular season left. Burton was 34th in points coming into Saturday and with him winning, the Playoff format is once again coming into question. One of those drivers who might miss the Playoffs now is 23XI's Bubba Wallace. Denny chats about his driver's situation. Off the track, Trackhouse made big news announcing that they acquired a third charter for SVG. The guys chat about SVG's future and Zane Smith losing his ride for next year.For more Actions Detrimental content, head to our YouTube page: https://www.youtube.com/@ActionsDetrimentalFanDuel disclaimer: 1+ and present in North Carolina. Opt in req. Wager requirements apply. Bonuses awarded as nonwithdrawable bonus bets or profit boost tokens. Restrictions apply including bonus expiration. See terms and conditions at fanduel.com/sportsbook. Gambling problem? Call 877-718-5543 or visit morethanagame.nc.gov.

On this episode of Good Nurse Bad Nurse, Tina and her guest host (also her son!) Joel discuss the tragic story of actor Matthew Perry's death and the recent arrests made in connection with it. For our "Good Nurse" segment, we're featuring Dr. Carlos Zarate and his study of the positive impact of ketamine treatment for some individuals with treatment-resistant depression (TRD).   Join us on Patreon to get ad-free episodes, early access, and more exclusive content!   Please support our show by supporting our sponsors below! Thanks to our sponsor Advantis Medical! Visit their website at https://www.advantismed.com/?utm_source=goodnursebadnurse&utm_medium=podcast&utm_campaign=spot1 to learn more about their travel nurse agency and why they're ranked #1 by nurses! Thank you to our sponsor Collaborating Docs! Visit http://www.collaboratingdocs.com/ to get a free quote with one of their onboarding specialists. Also, you can use the promo code “goodnurse” to get $250 off your onboarding fee! Thank you to our sponsor Eko! Please visit them at https://ekohealth.com and use promo code GNBN for $50 off your purchase of the new Littmann Cardiology IV stethoscope with Eko

EPISODE NOTES In this episode, hosts John Reade and Joe Cavatoni from the World Gold Council interview Marie Lemay, President and CEO, Royal Canadian Mint and Rob Sargent, Director Refinery Services, Royal Canadian Mint. Lemay discusses the role of the Royal Canadian Mint in the Canadian and broader gold industry and highlights several key initiatives and priorities for the Mint. As the group dives further into the conversation, Sargent highlights how the Royal Canadian Mint's legacy, with over 100 years of business in Ottawa, makes its refining facilities unique. The conversation then focuses on digitalization and the future of the gold industry, sharing insights on Distributed Ledger Technology (DLT) and the benefits it could bring to the precious metals industry.   [2:42] Marie shares how the Royal Canadian Mint supports the precious metals and refinery industry. [7.59] John and Joe discuss how WGC members and the broader gold industry are exploring the use of DLT for enhanced supply chain transparency [8:43] Rob discusses the digitalization of gold in the supply chain and how it could be impactful. [10:20] What are the benefits that Distributed Ledger Technology could bring to the industry? [18:10] What is the Royal Canadian Mint's involvement with LBMA and WGC's pilot GBI program? [19:19] Rob mentions the Bullion Genesis Project. Learn more about that here. [27:23] Rob shares his fun fact about gold.   Additional Resources: www.gold.org www.mint.ca Marie Lemay LinkedIn Rob Sargent LinkedIn Press release: World Gold Council members commit to enhanced supply-chain transparency Press release: The Royal Canadian Mint transforms its gold refining with new distributed ledger technology solution that traces metal from mine to vault More on the Bullion Genesis Project   Notable Quotes: “We pride ourselves on our responsible metal sourcing and we seek to attract refining customers who share our environmental, social and governance values.” -Marie Lemay “As the supply chain grows and more participants get onto a digitized supply chain, then I think you have opportunities to streamline data flow as well.” -Rob Sargent “We've been in the refining business here in downtown Ottawa for over 100 years, started in 1911, so there's that brand recognition.”  -Rob Sargent “I think the overall value of transparency sort of outweighs the competitive advantage.” -Rob Sargent About World Gold Council We are a membership organization that champions the role gold plays as a strategic asset, shaping the future of a responsible and accessible gold supply chain. Our team of experts builds understanding of the use case and possibilities of gold through trusted research, analysis, commentary, and insights. We drive industry progress, shaping policy and setting the standards for a perpetual and sustainable gold market. You can follow the World Gold Council on X at @goldcouncil and LinkedIn. Terms & Conditions | World Gold Council --- Unearthed : Le parcours de l'or, de la mine jusqu'à la chambre forte », avec Marie Lemay et Rob Sargent de la Monnaie royale canadienne   NOTES SUR L'ÉPISODE Dans cet épisode, les animateurs John Reade et Joe Cavatoni du World Gold Council s'entretiennent avec Marie Lemay, présidente de la Monnaie royale canadienne, et Rob Sargent, directeur des services d'affinage de la Monnaie royale canadienne. Marie Lemay parle du rôle de la Monnaie dans l'industrie de l'or au Canada et ailleurs, et présente quelques-unes des grandes initiatives et priorités de l'entreprise. Au fil de l'entretien, Rob Sargent explique comment le parcours de la Monnaie royale canadienne, qui mène ses activités à Ottawa depuis plus de 100 ans, rend ses installations d'affinage uniques en leur genre. La conversation se tourne ensuite vers la numérisation et l'avenir de l'industrie, notamment sur la technologie de registre distribué (TRD) et les avantages qu'elle pourrait apporter au secteur des métaux précieux.   [2:42] Marie Lemay explique comment la Monnaie royale canadienne soutient les secteurs des métaux précieux et de l'affinage. [7:59] John Reade et Joe Cavatoni expliquent que les membres du WGC et l'industrie de l'or dans son ensemble se penchent sur l'utilisation de la TRD pour améliorer la transparence au sein de la chaîne d'approvisionnement. [8:43] Rob Sargent discute de la numérisation de l'or au sein de la chaîne d'approvisionnement et de ses retombées. [10:20] Quels avantages la technologie de registre distribué pourrait-elle avoir pour l'industrie? [18:10] Quel est le rôle de la Monnaie royale canadienne dans le programme pilote d'intégrité des lingots d'or de la LBMA et du WGC? [19:19] Rob Sargent mentionne le projet Origine – Produits d'investissement. Pour en savoir plus, cliquez ici. [27:23] Rob Sargent raconte un fait intéressant sur l'or.   Ressources complémentaires www.gold.org https://www.monnaie.ca Page LinkedIn de Marie Lemay Page LinkedIn de Rob Sargent Communiqué de presse (en anglais seulement) : World Gold Council members commit to enhanced supply-chain transparency Communiqué de presse : La Monnaie royale canadienne transforme ses affineries d'or avec une nouvelle solution, la technologie de registre distribué, qui assure le suivi des métaux de la mine jusqu'au produit fini En savoir plus sur le Projet Origine – Produits d'investissement   Extraits de l'épisode « Nous sommes fiers de notre approvisionnement responsable en métaux et cherchons à attirer une clientèle d'affinage qui partage nos valeurs en ce qui concerne les facteurs environnementaux, sociaux et de gouvernance. » – Marie Lemay « À mesure que la chaîne d'approvisionnement s'accroît et que de plus en plus de participants mettent en place une chaîne d'approvisionnement numérique, nous avons aussi une occasion de simplifier le flux de données. » – Rob Sargent « Nous offrons des services d'affinage ici, au centre-ville d'Ottawa, depuis 1911, soit depuis plus de 100 ans. Nous jouissons donc d'une grande notoriété. » – Rob Sargent « Je crois que la valeur globale de la transparence l'emporte sur l'avantage concurrentiel. » – Rob Sargent À propos du World Gold Council Nous sommes une association mutuelle qui fait la promotion de l'or comme actif stratégique, façonnant ainsi l'avenir d'une chaîne d'approvisionnement de l'or responsable et accessible. Notre équipe d'experts étudie les cas d'utilisation et les possibilités relatives à l'or en fournissant des recherches, des analyses, des commentaires et des observations dignes de confiance. Nous faisons avancer l'industrie, influençons les politiques et établissons les normes pour un marché de l'or pérenne et durable. Vous pouvez suivre le World Gold Council sur X à @goldcouncil et sur LinkedIn. Modalités | World Gold Council (en anglais seulement)

Use AI to Speed up Your Work Flow Ethically and Securely. There are lots of courses on AI out there, but this one is specific only to medical writing and editing.  Access the AIMWE course waitlist. https://www.learnamastyle.com/waitlist/ Leqselvi for Alopecia Areata: The FDA has approved deuruxolitinib (Leqselvi) as a first-line treatment for adults with moderate to severe alopecia areata (AA). Developed by Sun Pharma, this oral selective inhibitor of Janus kinases JAK1 and JAK2 is typically dosed at 8 mg twice daily. The approval, based on the THRIVE-AA1 and THRIVE-AA2 trials, marks an important addition to limited treatment options for AA, which has significant psychological impacts. Femlyv Dissolvable Birth Control: The FDA has approved norethindrone acetate and ethinyl estradiol (Femlyv) as an oral dissolvable birth control pill, expanding access for those who have difficulty swallowing. This form of hormonal birth control, in use since 1968 as a swallowable tablet, also helps manage conditions like endometriosis and PMDD. The approval, based on a study of 743 women, offers a new option with common side effects like headache and nausea. Brineura for Batten Disease: The FDA has expanded the indication for cerliponase alfa (Brineura) to treat neuronal ceroid lipofuscinosis type 2 (CLN2 disease) in children under 3 years of age. Developed by BioMarin Pharmaceutical, this enzyme replacement therapy, initially approved in 2017, is administered by infusion into the brain. The expanded approval was based on a phase 2 trial showing reduced motor function decline and delayed disease onset. Erzofri for Schizophrenia: The FDA has approved paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia and schizoaffective disorder in adults. This long-acting injectable (LAI) antipsychotic, administered once a month, improves patient adherence by reducing dosing frequency. Developed by Luye Pharma Group, it was granted a U.S. patent in 2023 and approved under the 505(b)(2) pathway. Eque-cel for MS: The FDA has approved the IND application for equecabtagene autoleucel (Eque-cel) for treating multiple sclerosis (MS). Developed by IASO Biotechnology, this chimeric antigen receptor autologous T cell injection showed promising efficacy in six autoimmune diseases in a Chinese trial. MS, affecting 3.07 million people worldwide, is characterized by CNS demyelination and neuronal injury, with Eque-cel offering a new treatment option. Spravato for TRD: Johnson & Johnson has submitted an sNDA for esketamine (Spravato) as a monotherapy for adults with treatment-resistant depression (TRD). Already approved in combination with an oral antidepressant, esketamine is an NMDA receptor antagonist that rapidly alleviates depressive symptoms. The submission is based on Phase 4 TRD4005 study results, showing rapid improvement in depression scores with a consistent safety profile. ZW191 Anti-Tumor Agent: The FDA has cleared the IND application for ZW191, a novel antibody-drug conjugate (ADC) targeting folate receptor alpha (FR⍺) in cancers like gynecologic and NSCLC. Developed by Zymeworks, this TOPO1i ADC uses a novel payload, ZD06519, showing robust antitumor activity and a tolerable safety profile in preclinical models. Clinical development of ZW191 is planned to begin in the second half of 2024.

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial  Nature Medicine The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration. In this phase 2 multicenter clinical trial, male and female adult patients with treatment-resistant major depression (TRD) and Montgomery–Asberg Depression Rating Scale (MADRS) scores ≥20 received open-label R-107 tablets 120 mg per day for 5 days and were assessed on day 8 (enrichment phase). On day 8, responders (MADRS scores ≤12 and reduction ≥50%) were randomized to receive double-blind R-107 doses of 30, 60, 120, or 180 mg, or placebo, twice weekly for 12 weeks. Nonresponders on day 8 exited the study. Tolerability was excellent, with no changes in blood pressure, minimal reports of sedation, and minimal dissociation. The most common adverse events were headache, dizziness, and anxiety. R-107 tablets were effective, safe, and well tolerated in patients with TRD, enriched for initial response to R-107 tablets.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

If you're dealing with the heavy clouds of treatment-resistant depression (TRD) or generalized anxiety disorder (GAD), Elevated Medicine (+1 970 749 4443) has a silver lining for you—ketamine infusions. These treatments could be your beacon of hope. Elevated Medicine City: Durango Address: 3750 Main Ave Website: https://www.elevatedmedicine.org/ Phone: +1-970-749-4443 Email: info@elevatedmedicine.org

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/identifying-and-managing-treatment-resistant-depression-9471Summary“Difficult-to-Treat” Depression (DTD) also referred as “treatment-resistant depression” (TRD) are two terms used interchangeably but with distinct implications for therapeutic decisions and treatment strategies. In addition to focusing on symptom control, interventions for difficult-to-treat depression (DTD) should also address other factors, such as managing psychiatric and medical comorbidities, however, erroneous diagnosis and lack of treatment adherence had led to a variety of DTD outcomes.In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the evolving neurologic basis of depression and empower clinicians with convergent evidence about the pathophysiology and appropriate treatment options of “difficult-to-treat depression” (DTD) and “treatment-resistant-depression” (TRD) to inform therapeutic decisions.This podcast/webcast was recorded and is being used with permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to: Review the evolving genetic and neurologic basis of depressionDistinguish between “difficult-to-treat” and “treatment-resistant” depression to inform therapeutic decisions, and appropriate treatment optionsThis activity is accredited for CME/CE CreditThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is not commercially supported.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

It's not just tax credits. It's not just zoning by right. To make office-to-residential conversion projects work, developers need all of the above, says Bobby Fijan of Philadelphia-based Form Developers. TRD's Deconstruct chatted with Fijan about some of the legislation, policies, subsidies and programs across the country that have helped push these conversions forward.

Tachyphylaxis is a phenomenon described as the loss of response to a medication that was previously effective at an established dose. In a case report letter to the editors, Stefanie Cavalcanti, MD, Olga A. Lopez, MD, Simon Kung, MD, Jennifer L. Vande Voort, MD, Kristin Somers, MD, Mark A. Frye, MD, and Balwinder Singh, MD, MS, from the department of psychiatry and psychology at the Mayo Clinic, in Rochester, Minnesota, discuss “A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression” in the May/June 2024 issue of the Journal of Clinical Psychopharmacology. In this podcast about the case report, two co-authors, Dr. Singh and Dr. Cavalcanti, discuss the compelling history of one 56-year-old woman with treatment-resistant recurrent major depressive disorder. Her depression, ongoing for 10 years, featured prominent symptoms of depressed mood, social isolation, low energy, decreased appetite, and anhedonia. Past medication trials included selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, mood stabilizers, antipsychotics, benzodiazepines, and bitemporal electroconvulsive therapy with limited benefit. Ketamine, which is used increasingly for treatment-resistant depression (TRD), and other psychiatric disorders, was tried next. Sustained clinical response was observed for the first 2 years of intravenous ketamine treatment despite ongoing life stressors. In the following years, a gradual reduction of response to subsequent ketamine infusions was observed in the patient, who required more frequent infusions to obtain the same response. The authors emphasize that “the extension of ketamine's antidepressant effect with an increased dosage remains uncertain. … Ketamine has an addiction potential; thus, it is important to be mindful that increasing the ketamine dosage to address ketamine tachyphylaxis may enhance the potential for undesired consequences. Urgent studies investigating strategies to prolong ketamine's efficacy in adults with TRD are required.”

Once one of the most innovative and pioneering male seiyuu units in the industry, TRD (from 2012 up until 2020 was called D.A.T) now bids goodbye to their fans. The duo announced the release of their 1st album as well as their disbandment effective immediately after June 2024. After this news hit the industry, and seeing how many seiyuu units have disbanded in the past couple of years, is the end of this pioneering seiyuu unit, the end of an era for seiyuu units? Let's talk about that and the reasons behind the sudden disappearance of many seiyuu units in recent years in this episode of SEIYUU LOUNGE. Did you enjoy this episode? Consider ranking this podcast or leaving a review on your preferred podcast streaming platform!

When the National Association of Realtors announced it had proposed to settle a landmark antitrust suit over real estate agent commissions for $418 million, everyone had questions. The Real Deal's Deconstruct breaks down what is changing — and what is not. TRD reporters Sheridan Wall and Harrison Connery discuss NAR's new rule prohibiting broker compensation offers on the MLS, or multiple listing service, and what this means for agents and homebuyers going forward. Deconstruct also chatted with Michael Nourmand, who runs Los Angeles-based brokerage Nourmand & Associates, about how he thinks not much is set to change — and noted that commissions have always been negotiable.

Have you tried medication after medication to find that nothing works? Don't lose hope! You can now manage your TRD with ketamine IV therapy from Chrysalis Ketamine (888-836-4334). Learn more at https://chrysalisketamine.com/depression-treatment-thousand-oaks-ca/ Chrysalis Ketamine City: Thousand Oaks Address: 430 E Avenida De Los Arboles Suite 205 Website: https://www.chrysalisketamine.com Phone: +1-888-836-4334 Email: hkarpanian@gmail.com

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomed Dr Hans Eriksson, chief medical officer at HMNC Brain Health, a precision psychiatry biopharma company, to discuss his work exploring current studies into the use of ketamine in mental health, HMNC Brain Health having last year announced topline results from a Phase 2 study looking at a take-at-home, oral ketamine option for Treatment Resistant Depression (or TRD).

Isabella Robusto joined the Toyota Racing Development Program in 2022 where she will run a full-time Late Model schedule with Lee Faulk Racing. Before joining TRD, Isabella was the youngest driver ever to be selected as part of the NASCAR Drive for Diversity program at the age of 12, with the program for 5 consecutive years: making her the longest-running ever driver in the program. Today, following a setback crash, she's back to one hundred percent and ready to run up front again. Connect with Isabella here: Web: https://www.isabellarobusto.com/Facebook: https://www.facebook.com/isabellarobusto/Twitter: https://twitter.com/IsabellaRobusto Instagram: https://www.instagram.com/isabellarobusto55/ More about Youth Racers of America:https://youthracersofamerica.com/Connect with JP Emerson:Website: www.jpemerson.com Twitter: @The_JPEmersonEmail: jp@jpemerson.com For more podcasts on cars checkout Ford Mustang The Early Years Podcast at www.TheMustangPodcast.com or atApple Podcasts or anywhere you get your podcastsFor more information aboutsponsorship or advertising on The JP Emerson Show or podcast launch servicescontact Doug Sandler at doug@turnkeypodcast.com or visit www.turnkeypodcast.com

Ob kopičenju stavk nezadovoljnih skupin bodo danes za pogajalsko mizo po daljšem času sedli predstavniki vlade in sindikatov javnega sektorja. Finančni minister Klemen Boštjančič napoveduje, da se ne bodo pogovarjali le o višini plač in razmerjih, ampak tudi o normativih in učinkovitosti dela. Drugi poudarki oddaje: - V luči financ se vlada zavzema za kompromisne rešitve. Trd oreh bodo zdravniki, ki vztrajajo pri ločenem plačnem stebru. Veliko finančno obremenitev bi tako lahko povzročilo zvišanje njihovih plač, če ga bodo na pogajanjih dosegli. - Turški parlament je podprl pristopni protokol Švedske k zvezi Nato. Edina članica, ki ga še ni ratificirala, je tako Madžarska. - Slovenski rokometaši so si z zmago proti Danski na Euru zagotovili tekmo za peto mesto in nastop na kvalifikacijskem turnirju za olimpijske igre. Odličen je bil tudi alpski smučar Žan Kranjec. Na sinočnjem veleslalomu v Schladmingu je bil tretji.

Pull back the cover of The Real Deal's January issue and you'll find NIMBY vs. YIMBY battles unfolding across the country. Deconstruct talks with TRD senior reporters and bureau chiefs to unpack what's driving development and blocking construction in New York, South Florida, Los Angeles, Austin and Chicago.

David Wilson, President of Toyota Racing Development USA. Wilson is responsible for all TRD operations and activities in North America which include engine engineering, manufacturing, administration, chassis engineering, and operations. https://www.epartrade.com/more/onlineraceindustryweek From EPARTRADE, RACER.com, & SPEED SPORT. Presented by ETS Racing Fuels, Fifth Third Bank Motorsports, Peak, Penske Racing Shocks, Scott Lewis Associates, and Total Seal Piston Rings. Sponsored by ARP, Performance Plus Global Logistics, and Shopmonkey.

In this week's episode, Raquel and Jennifer speak with guest Candace Oglesby about how ketamine and other psychedelics can be utilized alongside therapy. Candace Oglesby is the program director for Fluence Trainings Ketamine Assisted Psychotherapy (KAP) certificate program and a licensed professional counselor (LCPC) in the state of Maryland. Candace began her career as a psychedelic-assisted therapist in 2020, when she sat on her first study as a clinical trial therapist, which studied the effects of psilocybin in cancer and TRD patients. Since then, she has gained training in Ketamine, MDMA, and 5- MeO- DMT assisted therapies. In addition, Candace is the founder and owner of Jurnee Mental Health Consulting, LLC, a consulting business that provides support to individuals and businesses looking to deepen their understanding of mental health while also providing support and resources to global majority communities.  Candace also serves as a DEI mental health consultant, trainer, speaker, and mentor within the psychedelic community. When Candace is not acting as psychotherapist, consultant, trainer, and mentor, she is spending time with her husband, family, and friends. Candace believes that cutting-edge therapies and techniques should be made available to everyone despite race, sexual orientation, gender, or socio-economic status. Where to find Candace:Website: www.jurneewithcandace.comLet Raquel and Jennifer know what you think about this and other episodes of Madness Cafe on IG @madnesscafepodcast or by email at madnesscafepodcast@gmail.com.And don't forget to rate and review the show wherever you listen!Thanks for listening and responding!

On today's episode, we have Shane Norte (He/Him) join us for a conversation about the capitalization of healing. Together we talk about the psychedelic buffet, when a giraffe tries to give a polar bear advice on how to live, and the need for free access to earth-based medicines. If you enjoyed today's podcast, then please subscribe, leave a review, or share this podcast with a friend! To learn more, head over to the website : ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.modernanarchypodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ And if you want to connect deeper with the Modern Anarchy Family, then join the movement by becoming a part of the conscious objectors ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Your support is what powers this work and the larger societal change we are creating! Let's continue to challenge our assumptions and grow together. Join the community here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/user?u=54121384⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Transcript : https://www.modernanarchypodcast.com/post/the-healing-of-earth-based-medicines-with-shane-norte Intro and Outro Song: Wild Wild Woman by Your Smith Modern Anarchy Community: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ :⁠⁠⁠⁠⁠ www.modernanarchypodcast.com⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ : ⁠⁠⁠⁠⁠https://www.instagram.com/modernanarchypodcast⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ : ⁠⁠⁠⁠⁠https://www.patreon.com/user?u=54121384⁠⁠ Shane's Community: Church of the People : https://churchofthepeopleforcreatorandmotherearth.com/our-team Decriminalize Nature : ⁠https://www.decriminalizenature.org/Resources to Learn More: Medical Debt in the USA : https://www.thirdway.org/report/end-medical-debt#:~:text=Twenty%2Dfive%20percent%20of%20adults,adults%20have%20more%20medical%20debt. American Wealth Disparity : https://www.usatoday.com/story/money/2023/12/06/top-1-american-earners-more-wealth-middle-class/71769832007/ Decriminalize Nature : https://www.decriminalizenature.org/ COMP360 psilocybin treatment in TRD : https://compasspathways.com/our-work/comp360-psilocybin-treatment-in-trd/

It's never too early to get a jump start on your holiday shopping, especially when it comes to the gadgets that everyone will want this season. If you have a tech enthusiast on your holiday shopping list, find out the latest must-have items you need to start shopping for! Retail expert Justine Santaniello talks about her top tech gifts for the 2023 holiday season. Justine will showcase gifts that not only feature next-level technology, but also offer unique ways to spend quality time with family and friends through the holiday season and beyond. Clinical depression, also known as major depressive disorder (MDD), is one of the most common mental disorders in the United States. MDD symptoms may include depressed mood, loss of interest or pleasure in daily activities, change in sleep, appetite or weight, diminished concentration, feelings of worthlessness, decreased movement and slowed thoughts, suicidal ideation and/or fatigue or loss of energy. Approximately one-third of adults in the U.S. with MDD may have treatment-resistant depression (TRD) – which means they haven't responded adequately to two or more antidepressant medications during the same depressive episode.Dr. Chepke, a Board-Certified psychiatrist in Huntersville, North Carolina specializes in treating adult patients with treatment-resistant depression, and discusses the signs and symptoms of challenging-to-treat depression and outline a treatment option for treatment-resistant depression, including SPRAVATO® (esketamine) CIII nasal spray, along with the risks and benefits of taking the medication.Thanksgiving is the busiest travel week of the year when parents face the stress of traffic and sometimes the challenge of dealing with a child who is car sick. Pediatrician and Social Media Star, Dr. Mona Amin, identifies factors that can cause kids to feel queasy while traveling and provide tips for helping little ones avoid car sickness

Watch the full video interview on YouTube here: https://youtu.be/mUlwb2dbUms Dr. Mark Burhenne (IG: @askthedentist) is a bestselling author. He's a family and sleep medicine dentist who has been in private practice nearly 35 years. Dr. B has focused on patient-centered and preventative dental healthcare. He is the creator of Ask the Dentist, which is dedicated to exploring the mouth-body connection and the role of the oral microbiome.  In this episode, we discuss: Oral health impacts overall health Is your oral care routine sabotaging your health? Maintaining a healthy oral microbiome is critical Dr. B's daily oral care routine What to look for in an electric toothbrush The problem with some toothbrush bristles Proper brushing techniques Choosing the right toothbrush (manual or electric) What is hydroxyapatite toothpaste? Micro-hydroxyapatite vs. nano-hydroxyapatite The safest way to whiten your teeth Can you get fluoride out of your teeth? Is glycerin in toothpaste a problem? Avoid colloidal silver in toothpaste Is your toothpaste too abrasive? + How to check Relative Dentin Abrasion (RDA) Dr. B's approach to oil pulling Cavity prevention and remineralization Dr. B's healthy toothpaste recommendations Creating FYGG (Feed Your Good Guys) toothpaste Microplastics in dental floss + safe recommendations The benefits of mouth taping Addressing sleep apnea How a TRD (tongue retention device) can help with sleep apnea Everyone should get a sleep study Hybrid approaches for treating sleep apnea Show sponsor: BiOptimizers

This is a series of mixes to listen to during your ketamine therapy sessions, which have significantly impacted my own personal well-being and mental health. I've included soothing tracks that tickle your brain by layering in binaural brain wave frequencies. Headphones are strongly recommended. Enjoy! If you'd like to support me with this project, you can contribute using the link on my Soundcloud profile or by clicking the link below - this is a labor of love ❤️ https://cash.app/$iheartsarah https://www.paypal.com/paypalme/sarahmyersmusic Sarah Myers https://www.sarahmyersmusic.com/ __________________________________________ Ketamine therapy is widely gaining recognition in the scientific community and is regarded as a new frontier for treating patients with treatment-resistant depression (TRD), anxiety, suicidal ideation, and OCD. Ongoing studies show promising results in treating patients with TBIs, addiction, ADHD, alcoholism, and more. It is also being used to treat neuropathic pain, such as fibromyalgia. Learn more here: https://www.psycom.net/ketamine-depression Plant Medicine Podcast with Dr. Lynn Marie Morski https://www.plantmedicine.org/podcast Find a local ketamine clinic here: https://www.ketaminedirectory.com/ Find a Psychedelic Integration Therapist here: https://integration.maps.org/ Reddit Therapeutic Ketamine Community: https://www.reddit.com/r/TherapeuticKetamine/ Disclaimer: I am not a medical doctor, and this content is for informational or educational purposes only and does not substitute professional medical advice or consultations with healthcare professionals.

Resistant depression, also known as treatment-resistant depression (TRD), is a challenging and complex condition where individuals do not respond adequately to standard antidepressant treatments. It can be a frustrating and debilitating condition, but there are several approaches and strategies that can be considered to manage and treat resistant depression. Here are some general considerations for addressing resistant depressionIn one of this week's episodes on Weekly Dose with Dr. Ude, we have a special guest who will give us information about how to classify treatment-resistant depression.Dr. Vineka Heeramun is a dual board-certified Psychiatrist and internist who practices  as a inpatient and outpatient in Utah.She is also the founder and CEO of Joyful Horizon Psychiatry where she specializes in cutting edge treatments like Transcranial Magnetic Stimulation (TMS) for treatment resistant depression, OCD and anxiety and spravato (intranasal ketamine) for refractory  depression and acute suicidality.Her goal is to help patients feel joy and regain back their lives by mastering their mental health.Check it out!Here are the social media link of Dr. Vineka HeeramunIG: @joyfulhorizonFB: joyfulhorizonWebsite: joyfulhorizon.comLooking a quality primary-care physician?

Postpartum is such a significant time of change, adaptation, and bonding. It can also be a stressful, sleepless, and emotional time. I encourage you, if you're pregnant or hope to be, spend some time thinking through what you want the first 8 weeks postpartum to look like. If you're already postpartum, I would also encourage you to prioritize rest moving forward. And if you're beyond postpartum, consider how you might encourage or provide care/meals/rest for a new mom that you know.

Ketamine is among the most unique pharmaceutical agents on the market. Join us on an exploration of the research on its neuropharmacology and use for depression, and discussion of risks and benefits. References: Article referenced in the beginning: Martinez-Marmol, et al. Hericerin derivatives activates a pan neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spacial memory. Journal of Neurochemistry. 2023(165);6: 791-808   Ballard E and Zarate C. The role of disassociation in ketamine's anti-depressant effects. Nature Communications. 2020: 6431 Bobo WV, et al. Ketamine for treatment resistant unipolar and bipolar major depression: Critical review and implications for clinical practice. Depression and Anxiety. 6 April 2016. Esketamine [package insert]. Janssen Neuroscience. July 2023. Fava M, et al. Double blind, placebo controlled dose ranging trial of intravenous ketamine as adjunctive therapy in treatment resistant depression (TRD). Molecular Psychiatry. 2020(25): 1592-1603 Gales A, Maxwell S. Ketamine: recent evidence and clinical uses. World Federation of Societies of Anesthesiologists. 12 June 2018. Johnston JN, et al. Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology. 2023 Loo CK, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular, and subcutaneous routes for ketamine in depression. Acta Psychiatria Scandinavica. 30 March 2016. Mandal S, et al. Efficacy of Ketamine therapy in the treatment of depression. Indian Journal of Psychiatry. 2019 Sept-Oct; 61(5). VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office

What did a meta-analysis of studies assessing the safety and efficacy of vitrectomy for diabetic tractional retinal detachment (TRD) find when it comes to the rate of retinal reattachment and final visual acuity? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, outline the top-line findings of this meta-analysis, explore why the study's conclusions brush against conventional understandings of diabetic TRD outcomes following surgery, and ask whether the success bias of published studies undercut the real-world value of meta-analyses.  

It's the second full year of Craftsman Truck Series competition for Dean Thompson but his first in the No. 5 for Tricon Garage. Thompson breaks down how the year has gone; the difference in his progression as a driver; fitting into a new environment at Tricon; being surrounded by people (like Frank Kimmel) who are honest but helpful; ways that Tricon is different from other teams; the benefit of using the Toyota Performance Center; being big into boxing as a hobby; having a very structured schedule; getting started in racing then quitting and the reason why he came back; what the feeling was when getting back behind the wheel; racing across the country with his dad; how a young driver learns in a crazy series like trucks and who to lean on; owner David Gilliland having a drivers background; Tricon Garage letting Thompson be himself; controlling his emotions on camera after a few difficult moments this year; what has become a friendly rivalry with former foe Jesse Love; a fraternity amongst TRD drivers; future aspirations in racing; sharing a love of the (Mighty) Ducks. Music created by Tony Monge.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/3228370/advertisement

It's Friday! But even those two smile-inducing words just don't do it for a lot of people who are suffering from depression and its related disorders including anxiety and stress. Some of us have been battling at least one of those conditions for decades *including me.I was fascinated from the moment I heard that scientists were looking toward psychedelics to treat PTSD and some other mental health issues, and have kept an eye out for updates. Well, it's now 2023(!), and it's a lot more commonplace than most people realize.I'm one of those with TRD (treatment resistant depression), the prerequisite to be eligible for Spravado, the first FDA approved 'psychedelic' prescription to treat depression.I gave it a shot, and have been sharing the experience with my listeners.Today, I'm joined by Matt Lahn, the COO of Neuro Wellness Centers of America, the clinic where I've been getting my treatments, here in Coral Springs FL. Eventhough they're based in Coral Springs, Matt and Shelly are plugged into the mental health community and can help you find a good treatment center wherever you are. And Matt generously gave out his phone number should you have any questions about any of this. You can reach him directly at 954-709-1599.Great strides have been made in mental health treatment over the past few decades. And I know from experience that I'm part of a very large portion of the population who tries to put on a brave face each day while masking our inner blues. Plus every time I approach the subject of depression on the show, I get a lot of response.

Amir R. Korangy is an Iranian-American publisher and film producer, who founded the business magazine, The Real Deal, about real estate and finance news. He also produced the PBS documentary, "Building Stories", about architect Costas Kondylis. Amir Korangy is also an adjunct associate professor of media and real estate at New York University where in the fall of 2018 he will be teaching a course titled the Korangy sessions where graduate students will have an opportunity to court questions as to the reality of real estate in the city and the country, complementing to their theoretical framework.

RXR Realty CEO Scott Rechler's year has centered on "Project Kodak" — a strategy of separating older, obsolete office buildings from a younger product that can still pull the tenants and rents to thrive. TRD's Deconstruct sat down with Rechler to unpack how that strategy has evolved, why he's pegged multifamily as the next shoe to drop and whether the Fed's recent rate pause will lift the gates on investment sales. Credits: CBS New York

- Stellantis Only Shipping PHEVs To ZEV States - Ford Pro on Pace to Double Profits - Stellantis To Build eVTOLs Next Year - Nikola Lays Off Employees to Cut Costs - Faraday Delays Deliveries Again - Polestar Partners to Create New OS For China - Renault Unveils New SUV - Toyota Reveals New TRD Paint Color - New Acura Integra Type S Starts At $52,000

Real estate is a sport in Palm Beach. And billionaires are still making moves, despite an overall slowdown in home buying across the country. The luxury market in the South Florida town has been propelled by "inter-island moves" — wealthy homebuyers hopping from one mansion to the next. Deconstruct chats with TRD senior reporter Katherine Kallergis about why Palm Beach is continuing to see record deals trade and the most expensive listing currently on the market in the area.

Brandon Sheppard and crew have got their arms around the Longhorn Chassis and it was evident on Monday night at Farmer City. We'll talk about that plus an impressive night for Gordy Gundaker, Flo series and High Limit tonight, and an update on the TRD sprint car engine program.

There is much evidence pointing to a relationship between increased trade and improved socio-economic factors like income, poverty, equality, and the environment. But there's a disturbing trend afoot. World trade (measured as exports and imports as a fraction of world GDP) is down 5% since 2011, and US trade is down 20% over the same period. Worse, prior to 2011, US trade was on a solid upward trajectory for a couple of decades. From 2011 on, had US trade continued to grow at its historical rate, it would be 30% more today than it is.   Get Your Copy of Cooperation and Coercion Now! http://www.cooperationandcoercion.com See More Ant and James! http://www.wordsandnumbers.org Show Your Support for Words & Numbers at Patreon https://www.patreon.com/wordsandnumbers Apply for the Seminar on Classical Liberalism: Theory and Practice https://www.wabash.edu/stephenson-institute/summer-seminars James and Ant are at Basis Scottsdale this week https://data.worldbank.org/indicator/NE.TRD.GNFS.ZS?locations=US https://data.worldbank.org/indicator/NE.TRD.GNFS.ZS https://enrollbasis.com/scottsdale/ Words & Numbers Backstage https://www.facebook.com/groups/130029457649243/ More James at Smoke & Stories https://www.youtube.com/playlist?list=PLjILow4-ZJpBV-NnmSusZJ_vCuzKUJ4Ig More Ant on YouTube https://www.youtube.com/antonydavies Let Us Know What You Think mailto:wordsandnumberspodcast@gmail.com Antony Davies on Twitter https://twitter.com/antonydavies James R. Harrigan on Twitter https://twitter.com/JamesRHarrigan #AntonyDavies #JamesRHarrigan #WordsAndNumbers #economics #government #politics #policy #libertarian #classicalliberal